Wyeth (WYE)

Wyeth engages in the discovery, development, manufacture, distribution, and sale of pharmaceuticals, consumer healthcare, and animal health products. It operates through three segments: Pharmaceuticals, Consumer Healthcare, and Animal Health. The Pharmaceuticals segment offers human ethical pharmaceuticals, biotechnology products, vaccines, and nutrition products. Its principal products include neuroscience therapies, vaccines, musculoskeletal therapies, nutrition products, gastroenterology drugs, anti-infectives, oncology therapies, hemophilia treatments, immunological products, and women’s health care products. The Consumer Healthcare segment provides over-the-counter health care products comprising analgesics, cough/cold/allergy remedies, nutritional supplements, as well as hemorrhoidal, asthma, and personal care items. The Animal Health segment offers animal biological and pharmaceutical products consisting of vaccines, pharmaceuticals, parasite control products, and growth implants. The company sells its products to wholesalers, pharmacies, hospitals, physicians, retailers, and other health care institutions worldwide. Wyeth has collaboration agreements with Progenics Pharmaceuticals, Inc. and Trubion Pharmaceuticals, Inc. The company was founded in 1926 and is headquartered in Madison, New Jersey.

For the nine months ended 30 September 2006, Wyeth's revenues increased 8% to $15.13B. Net income increased 14% to $3.34B. Revenues reflect an increase in Pharmaceuticals sales. Net income also reflects improved gross margins and inclusion of net interest income vs. a loss. Wyeth is engaged in discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products & non-prescription medicines.